{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T08:02:41Z","timestamp":1767772961083,"version":"3.37.3"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T00:00:00Z","timestamp":1650240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T00:00:00Z","timestamp":1650240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970187","81920108006","82170193","81900203"],"award-info":[{"award-number":["81970187","81920108006","82170193","81900203"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences","award":["2019-I2M-2-009","2021-I2M-C&T-B-081"],"award-info":[{"award-number":["2019-I2M-2-009","2021-I2M-C&T-B-081"]}]},{"name":"National Science and Technology Major Project of China","award":["2017ZX09304024"],"award-info":[{"award-number":["2017ZX09304024"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s00277-022-04795-x","type":"journal-article","created":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T17:05:55Z","timestamp":1650301555000},"page":"1201-1210","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Purine nucleoside analogs plus rituximab are an effective treatment choice for hairy cell leukemia-variant"],"prefix":"10.1007","volume":"101","author":[{"given":"Yi","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tingyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuting","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ru","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjie","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiwei","family":"Sui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenyang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huijun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengwen","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dehui","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"An","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianxiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lugui","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuhua","family":"Yi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,18]]},"reference":[{"issue":"1","key":"4795_CR1","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/sj.leu.2401999","volume":"15","author":"E Matutes","year":"2001","unstructured":"Matutes E, Wotherspoon A, Brito-Babapulle V, Catovsky D (2001) The natural history and clinico-pathological features of the variant form of hairy cell leukemia. Leukemia 15(1):184\u2013186. https:\/\/doi.org\/10.1038\/sj.leu.2401999","journal-title":"Leukemia"},{"issue":"6","key":"4795_CR2","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1016\/j.clml.2019.11.002","volume":"20","author":"Y Yan","year":"2020","unstructured":"Yan Y, Lv R, Xiong W, Li Z, Wang Y, Yu Y, Yu Z, Wang T, Sui W, Liu W, Zou D, Yi S, Qiu L (2020) Subtype distribution, clinical features, and survival in b-cell chronic lymphoproliferative disorders in china: a review of 1592 cases. Clin Lymphoma Myeloma Leuk 20(6):e270\u2013e283. https:\/\/doi.org\/10.1016\/j.clml.2019.11.002","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"4795_CR3","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/0145-2126(80)90066-1","volume":"4","author":"JC Cawley","year":"1980","unstructured":"Cawley JC, Burns GF, Hayhoe FG (1980) A chronic lymphoproliferative disorder with distinctive features: a distinct variant of hairy-cell leukaemia. Leuk Res 4(6):547\u2013559. https:\/\/doi.org\/10.1016\/0145-2126(80)90066-1","journal-title":"Leuk Res"},{"issue":"1","key":"4795_CR4","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1001\/jamaoncol.2015.4134","volume":"2","author":"A Sarvaria","year":"2016","unstructured":"Sarvaria A, Topp Z, Saven A (2016) Current therapy and new directions in the treatment of hairy cell leukemia: a review. JAMA Oncol 2(1):123\u2013129. https:\/\/doi.org\/10.1001\/jamaoncol.2015.4134","journal-title":"JAMA Oncol"},{"issue":"4","key":"4795_CR5","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.beha.2015.10.019","volume":"28","author":"A Wotherspoon","year":"2015","unstructured":"Wotherspoon A, Attygalle A, Mendes LST (2015) Bone marrow and splenic histology in hairy cell leukaemia. Best Pract Res Clin Haematol 28(4):200\u2013207. https:\/\/doi.org\/10.1016\/j.beha.2015.10.019","journal-title":"Best Pract Res Clin Haematol"},{"issue":"11","key":"4795_CR6","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1038\/s41379-018-0093-8","volume":"31","author":"EA Angelova","year":"2018","unstructured":"Angelova EA, Medeiros LJ, Wang W, Muzzafar T, Lu X, Khoury JD, Ravandi F, Patel KP, Hu Z, Kanagal-Shamanna R (2018) Clinicopathologic and molecular features in hairy cell leukemia-variant: single institutional experience. Mod Pathol 31(11):1717\u20131732. https:\/\/doi.org\/10.1038\/s41379-018-0093-8","journal-title":"Mod Pathol"},{"issue":"1","key":"4795_CR7","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1182\/blood.V76.1.157.157","volume":"76","author":"L Sainati","year":"1990","unstructured":"Sainati L, Matutes E, Mulligan S, de Oliveira MP, Rani S, Lampert IA, Catovsky D (1990) A variant form of hairy cell leukemia resistant to alpha-interferon: clinical and phenotypic characteristics of 17 patients. Blood 76(1):157\u2013162. https:\/\/doi.org\/10.1182\/blood.V76.1.157.157","journal-title":"Blood"},{"issue":"4","key":"4795_CR8","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.beha.2015.09.002","volume":"28","author":"E Matutes","year":"2015","unstructured":"Matutes E, Martinez-Trillos A, Campo E (2015) Hairy cell leukaemia-variant: disease features and treatment. Best Pract Res Clin Haematol 28(4):253\u2013263. https:\/\/doi.org\/10.1016\/j.beha.2015.09.002","journal-title":"Best Pract Res Clin Haematol"},{"issue":"20","key":"4795_CR9","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD, Jaffe ES (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127(20):2375\u20132390. https:\/\/doi.org\/10.1182\/blood-2016-01-643569","journal-title":"Blood"},{"issue":"6","key":"4795_CR10","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1002\/ccr3.2176","volume":"7","author":"M Wiber","year":"2019","unstructured":"Wiber M, Maitre E, Cornet E, Sala\u00fcn V, Naguib D, Troussard X (2019) Variant form of hairy cell leukemia. Clin Case Rep 7(6):1161\u20131166. https:\/\/doi.org\/10.1002\/ccr3.2176","journal-title":"Clin Case Rep"},{"issue":"3","key":"4795_CR11","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/bjh.12490","volume":"163","author":"R Chandran","year":"2013","unstructured":"Chandran R, Gardiner SK, Smith SD, Spurgeon SE (2013) Improved survival in hairy cell leukaemia over three decades: a SEER database analysis of prognostic factors. Br J Haematol 163(3):407\u2013409. https:\/\/doi.org\/10.1111\/bjh.12490","journal-title":"Br J Haematol"},{"issue":"5","key":"4795_CR12","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1111\/bjh.17055","volume":"191","author":"N Parry-Jones","year":"2020","unstructured":"Parry-Jones N, Joshi A, Forconi F, Dearden C (2020) Guideline for diagnosis and management of hairy cell leukaemia (HCL) and hairy cell variant (HCL-V). Br J Haematol 191(5):730\u2013737. https:\/\/doi.org\/10.1111\/bjh.17055","journal-title":"Br J Haematol"},{"issue":"1","key":"4795_CR13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/bjh.17201","volume":"193","author":"X Troussard","year":"2021","unstructured":"Troussard X, Grever MR (2021) The revised guidelines for the diagnosis and management of hairy cell leukaemia and the hairy cell leukaemia variant. Br J Haematol 193(1):11\u201314. https:\/\/doi.org\/10.1111\/bjh.17201","journal-title":"Br J Haematol"},{"issue":"1","key":"4795_CR14","doi-asserted-by":"publisher","first-page":"72","DOI":"10.3109\/10428194.2010.531411","volume":"52","author":"S Yi","year":"2011","unstructured":"Yi S, Yu Z, Zhou K, Wang Y, An G, Li Z, Zou D, Qi J, Zhao Y, Chan WC, Qiu L (2011) TOSO is overexpressed and correlated with disease progression in Chinese patients with chronic lymphocytic leukemia. Leuk Lymphoma 52(1):72\u201378. https:\/\/doi.org\/10.3109\/10428194.2010.531411","journal-title":"Leuk Lymphoma"},{"key":"4795_CR15","doi-asserted-by":"publisher","DOI":"10.1159\/isbn.978-3-318-06861-0","volume-title":"ISCN 2016: An International System for Human Cytogenomic Nomenclature (2016)","author":"J McGowan-Jordan","year":"2016","unstructured":"McGowan-Jordan J, Simons A, Schmid M (2016) ISCN 2016: An International System for Human Cytogenomic Nomenclature (2016). Karger, Basel. https:\/\/doi.org\/10.1159\/isbn.978-3-318-06861-0"},{"issue":"2","key":"4795_CR16","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/gim.2016.81","volume":"19","author":"S Yi","year":"2017","unstructured":"Yi S, Li Z, Zou D, An G, Cui R, Zhong S, Li H, Xiong W, Li C, Chen W, Liu W, Lv R, Yu Z, Wang H, Xu Y, Zhou K, Ru K, Wang J, Cheng T, Qiu L (2017) Intratumoral genetic heterogeneity and number of cytogenetic aberrations provide additional prognostic significance in chronic lymphocytic leukemia. Genet Med 19(2):182\u2013191. https:\/\/doi.org\/10.1038\/gim.2016.81","journal-title":"Genet Med"},{"issue":"3","key":"4795_CR17","doi-asserted-by":"publisher","first-page":"325","DOI":"10.7150\/ijms.39307","volume":"17","author":"R Zhang","year":"2020","unstructured":"Zhang R, Wu Y, Wang X, Lu X, Li Y, Li S, Yan X (2020) Difference of genomic copy numbers alterations between hairy cell leukemia-variant and classical hairy cell leukemia: a pilot retrospective study in Chinese. Int J Med Sci 17(3):325\u2013331. https:\/\/doi.org\/10.7150\/ijms.39307","journal-title":"Int J Med Sci"},{"issue":"1","key":"4795_CR18","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1309\/8qytyq1clqmhq9cl","volume":"123","author":"MH Cessna","year":"2005","unstructured":"Cessna MH, Hartung L, Tripp S, Perkins SL, Bahler DW (2005) Hairy cell leukemia variant: fact or fiction. Am J Clin Pathol 123(1):132\u2013138. https:\/\/doi.org\/10.1309\/8qytyq1clqmhq9cl","journal-title":"Am J Clin Pathol"},{"issue":"1","key":"4795_CR19","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1080\/10428194.2016.1185786","volume":"58","author":"EF Mason","year":"2017","unstructured":"Mason EF, Brown RD, Szeto DP, Gibson CJ, Jia Y, Garcia EP, Jacobson CA, Dal Cin P, Kuo FC, Pinkus GS, Lindeman NI, Sholl LM, Aster JC, Morgan EA (2017) Detection of activating MAP2K1 mutations in atypical hairy cell leukemia and hairy cell leukemia variant. Leuk Lymphoma 58(1):233\u2013236. https:\/\/doi.org\/10.1080\/10428194.2016.1185786","journal-title":"Leuk Lymphoma"},{"issue":"21","key":"4795_CR20","doi-asserted-by":"publisher","first-page":"4687","DOI":"10.1182\/blood-2009-01-201731","volume":"114","author":"E Arons","year":"2009","unstructured":"Arons E, Suntum T, Stetler-Stevenson M, Kreitman RJ (2009) VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy. Blood 114(21):4687\u20134695. https:\/\/doi.org\/10.1182\/blood-2009-01-201731","journal-title":"Blood"},{"issue":"1","key":"4795_CR21","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/ng.2828","volume":"46","author":"JJ Waterfall","year":"2014","unstructured":"Waterfall JJ, Arons E, Walker RL, Pineda M, Roth L, Killian JK, Abaan OD, Davis SR, Kreitman RJ, Meltzer PS (2014) High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias. Nat Genet 46(1):8\u201310. https:\/\/doi.org\/10.1038\/ng.2828","journal-title":"Nat Genet"},{"issue":"4","key":"4795_CR22","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.leukres.2012.11.021","volume":"37","author":"H Shao","year":"2013","unstructured":"Shao H, Calvo KR, Gr\u00f6nborg M, Tembhare PR, Kreitman RJ, Stetler-Stevenson M, Yuan CM (2013) Distinguishing hairy cell leukemia variant from hairy cell leukemia: development and validation of diagnostic criteria. Leuk Res 37(4):401\u2013409. https:\/\/doi.org\/10.1016\/j.leukres.2012.11.021","journal-title":"Leuk Res"},{"issue":"3","key":"4795_CR23","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1111\/j.1365-2141.2012.09163.x","volume":"158","author":"SL Hockley","year":"2012","unstructured":"Hockley SL, Else M, Morilla A, Wotherspoon A, Dearden C, Catovsky D, Gonzalez D, Matutes E (2012) The prognostic impact of clinical and molecular features in hairy cell leukaemia variant and splenic marginal zone lymphoma. Br J Haematol 158(3):347\u2013354. https:\/\/doi.org\/10.1111\/j.1365-2141.2012.09163.x","journal-title":"Br J Haematol"},{"issue":"2","key":"4795_CR24","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1002\/ajh.26390","volume":"97","author":"X Troussard","year":"2022","unstructured":"Troussard X, Maitre E, Cornet E (2022) Hairy cell leukemia 2022: update on diagnosis, risk-stratification, and treatment. Am J Hematol 97(2):226\u2013236. https:\/\/doi.org\/10.1002\/ajh.26390","journal-title":"Am J Hematol"},{"issue":"7","key":"4795_CR25","doi-asserted-by":"publisher","first-page":"162","DOI":"10.21037\/atm.2017.03.85","volume":"5","author":"MJ McKay","year":"2017","unstructured":"McKay MJ, Rady KL, McKay TA (2017) Hairy cell leukaemia variant with periarticular joint infiltration and excellent radiotherapy response. Annals Transl Med 5(7):162. https:\/\/doi.org\/10.21037\/atm.2017.03.85","journal-title":"Annals Transl Med"},{"issue":"4","key":"4795_CR26","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1080\/10428194.2017.1365853","volume":"59","author":"LA Andritsos","year":"2018","unstructured":"Andritsos LA, Grieselhuber NR, Anghelina M, Rogers KA, Roychowdhury S, Reeser JW, Timmers CD, Freud AG, Blachly JS, Lucas DM, Lozanski G, Jones JA, Williams K, Oakes C, Jones D, Grever MR (2018) Trametinib for the treatment of IGHV4-34, MAP2K1-mutant variant hairy cell leukemia. Leuk Lymphoma 59(4):1008\u20131011. https:\/\/doi.org\/10.1080\/10428194.2017.1365853","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"4795_CR27","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1002\/cyto.b.21785","volume":"96","author":"DA Salem","year":"2019","unstructured":"Salem DA, Scott D, McCoy CS, Liewehr DJ, Venzon DJ, Arons E, Kreitman RJ, Stetler-Stevenson M, Yuan CM (2019) Differential expression of CD43, CD81, and CD200 in classic versus variant hairy cell leukemia. Cytometry B Clin Cytom 96(4):275\u2013282. https:\/\/doi.org\/10.1002\/cyto.b.21785","journal-title":"Cytometry B Clin Cytom"},{"issue":"2\u20133","key":"4795_CR28","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s12026-014-8490-7","volume":"58","author":"S Levy","year":"2014","unstructured":"Levy S (2014) Function of the tetraspanin molecule CD81 in B and T cells. Immunol Res 58(2\u20133):179\u2013185. https:\/\/doi.org\/10.1007\/s12026-014-8490-7","journal-title":"Immunol Res"},{"issue":"5","key":"4795_CR29","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/j.hoc.2006.06.012","volume":"20","author":"E Matutes","year":"2006","unstructured":"Matutes E (2006) Immunophenotyping and differential diagnosis of hairy cell leukemia. Hematol Oncol Clin North Am 20(5):1051\u20131063. https:\/\/doi.org\/10.1016\/j.hoc.2006.06.012","journal-title":"Hematol Oncol Clin North Am"},{"issue":"14","key":"4795_CR30","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1182\/blood-2017-01-765107","volume":"130","author":"BH Durham","year":"2017","unstructured":"Durham BH, Getta B, Dietrich S, Taylor J, Won H, Bogenberger JM, Scott S, Kim E, Chung YR, Chung SS, Hullein J, Walther T, Wang L, Lu SX, Oakes CC, Tibes R, Haferlach T, Taylor BS, Tallman MS, Berger MF, Park JH, Zenz T, Abdel-Wahab O (2017) Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations. Blood 130(14):1644\u20131648. https:\/\/doi.org\/10.1182\/blood-2017-01-765107","journal-title":"Blood"},{"issue":"9","key":"4795_CR31","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1200\/JCO.2016.71.1556","volume":"35","author":"E Tiacci","year":"2017","unstructured":"Tiacci E, Pettirossi V, Schiavoni G, Falini B (2017) Genomics of hairy cell leukemia. J Clin Oncol 35(9):1002\u20131010. https:\/\/doi.org\/10.1200\/JCO.2016.71.1556","journal-title":"J Clin Oncol"},{"issue":"24","key":"4795_CR32","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1056\/NEJMoa1014209","volume":"364","author":"E Tiacci","year":"2011","unstructured":"Tiacci E, Trifonov V, Schiavoni G, Holmes A, Kern W, Martelli MP, Pucciarini A, Bigerna B, Pacini R, Wells VA, Sportoletti P, Pettirossi V, Mannucci R, Elliott O, Liso A, Ambrosetti A, Pulsoni A, Forconi F, Trentin L, Semenzato G, Inghirami G, Capponi M, Di Raimondo F, Patti C, Arcaini L, Musto P, Pileri S, Haferlach C, Schnittger S, Pizzolo G, Fo\u00e0 R, Farinelli L, Haferlach T, Pasqualucci L, Rabadan R, Falini B (2011) BRAF mutations in hairy-cell leukemia. N Engl J Med 364(24):2305\u20132315. https:\/\/doi.org\/10.1056\/NEJMoa1014209","journal-title":"N Engl J Med"},{"key":"4795_CR33","doi-asserted-by":"publisher","unstructured":"Liu Q, Harris N, Epperla N, Andritsos L A (2021) Current and emerging therapeutic options for hairy cell leukemia variant. Onco Targets Ther 2021(14):1797\u20131805. https:\/\/doi.org\/10.2147\/OTT.S242247","DOI":"10.2147\/OTT.S242247"},{"issue":"1","key":"4795_CR34","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/j.1600-0609.1999.tb01114.x","volume":"62","author":"T Robak","year":"1999","unstructured":"Robak T, B\u0142asi\u0144ska-Morawiec M, B\u0142o\u0144ski J, Hellmann A, Ha\u0142aburda K, Konopka L, Kotlarek-Haus S, Potoczek S, Hansz J, Dmoszy\u0144ska A, Urasi\u0144ski I, Zdziarska B, Dwilewicz-Trojaczek J, Ho\u0142owiecki J, Skotnicki AB (1999) 2-chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7-year experience in Poland. Eur J Haematol 62(1):49\u201356. https:\/\/doi.org\/10.1111\/j.1600-0609.1999.tb01114.x","journal-title":"Eur J Haematol"},{"issue":"1","key":"4795_CR35","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3324\/%25x","volume":"87","author":"L Palomera","year":"2002","unstructured":"Palomera L, Domingo JM, Sola C, Azaceta G, Calvo MT, Gutierrez M (2002) Cladribine (2-chlorodeoxyadenosine) therapy in hairy cell leukemia variant. A report of three cases. Haematologica 87(1):107\u2013108. https:\/\/doi.org\/10.3324\/%25x","journal-title":"Haematologica"},{"issue":"1","key":"4795_CR36","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3324\/%25x","volume":"87","author":"KU Chow","year":"2002","unstructured":"Chow KU, Sommerlad WD, Boehrer S, Schneider B, Seipelt G, Rummel MJ, Hoelzer D, Mitrou PS, Weidmann E (2002) Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases. Haematologica 87(1):33\u201343. https:\/\/doi.org\/10.3324\/%25x","journal-title":"Haematologica"},{"issue":"24","key":"4795_CR37","doi-asserted-by":"publisher","first-page":"6873","DOI":"10.1158\/1078-0432.CCR-13-1752","volume":"19","author":"RJ Kreitman","year":"2013","unstructured":"Kreitman RJ, Wilson W, Calvo KR, Arons E, Roth L, Sapolsky J, Zhou H, Raffeld M, Stetler-Stevenson M (2013) Cladribine with immediate rituximab for the treatment of patients with variant hairy cell leukemia. Clin Cancer Res 19(24):6873\u20136881. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-1752","journal-title":"Clin Cancer Res"},{"issue":"66","key":"4795_CR38","doi-asserted-by":"publisher","first-page":"110727","DOI":"10.18632\/oncotarget.21304","volume":"8","author":"A Visentin","year":"2017","unstructured":"Visentin A, Imbergamo S, Frezzato F, Pizzi M, Bertorelle R, Scomazzon E, Berno T, Riva M, Piva E, Facco M, Piazza F, Semenzato G, Trentin L (2017) Bendamustine plus rituximab is an effective first-line treatment in hairy cell leukemia variant: a report of three cases. Oncotarget 8(66):110727\u2013110731. https:\/\/doi.org\/10.18632\/oncotarget.21304","journal-title":"Oncotarget"},{"issue":"2","key":"4795_CR39","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/(SICI)1096-8652(199610)53:2<121::AID-AJH11>3.0.CO;2-I","volume":"53","author":"CH Dunphy","year":"1996","unstructured":"Dunphy CH, Petruska PJ (1996) Atypical prolymphocytic variant of hairy-cell leukemia: case report and review of the literature. Am J Hematol 53(2):121\u2013125. https:\/\/doi.org\/10.1002\/(SICI)1096-8652(199610)53:2%3c121::AID-AJH11%3e3.0.CO;2-I","journal-title":"Am J Hematol"},{"issue":"6","key":"4795_CR40","doi-asserted-by":"publisher","first-page":"5148","DOI":"10.3390\/curroncol28060431","volume":"28","author":"E Yilmaz","year":"2021","unstructured":"Yilmaz E, Chhina A, Nava VE, Aggarwal A (2021) A review on splenic diffuse red pulp small B-cell lymphoma. Curr Oncol 28(6):5148\u20135154. https:\/\/doi.org\/10.3390\/curroncol28060431","journal-title":"Curr Oncol"},{"issue":"7","key":"4795_CR41","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.3324\/haematol.2009.013714","volume":"95","author":"K George","year":"2010","unstructured":"George K, Manuela M, Santiago M-M, Socorro-Mar\u00eda R-P, Juan CC, Patricia A, Carlos M, Estella M, Andrew W, Miguel AP (2010) Splenic diffuse red pulp small B-cell lymphoma: revision of a series of cases reveals characteristic clinico-pathological features. Haematologica 95(7):1122\u20131129. https:\/\/doi.org\/10.3324\/haematol.2009.013714","journal-title":"Haematologica"},{"issue":"11","key":"4795_CR42","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1097\/PAS.0b013e318271243d","volume":"36","author":"M Ponzoni","year":"2012","unstructured":"Ponzoni M, Kanellis G, Pouliou E, Baliakas P, Scarf\u00f2 L, Ferreri AJM, Doglioni C, Bikos V, Dagklis A, Anagnostopoulos A, Ghia P, Stamatopoulos K, Papadaki T (2012) Bone marrow histopathology in the diagnostic evaluation of splenic marginal-zone and splenic diffuse red pulp small B-cell lymphoma: a reliable substitute for spleen histopathology? Am J Surg Pathol 36(11):1609\u20131618. https:\/\/doi.org\/10.1097\/PAS.0b013e318271243d","journal-title":"Am J Surg Pathol"},{"issue":"8","key":"4795_CR43","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1182\/blood-2016-11-751024","volume":"129","author":"S Curiel-Olmo","year":"2017","unstructured":"Curiel-Olmo S, Mond\u00e9jar R, Almaraz C, Mollejo M, Cereceda L, Mar\u00e8s R, Derdak S, Campos-Mart\u00edn Y, Batlle A, Gonz\u00e1lez de Villambros\u00eda S, Gut M, Blanc J, Traverse-Glehen A, Verney A, Baseggio L, Camacho FI, Wotherspoon A, Stamatopoulos K, Xochelli A, Papadaki T, Kanellis G, Ponzoni M, Garc\u00eda-Cos\u00edo M, Vaqu\u00e9 JP, Beltr\u00e1n S, Gut I, Piris MA, Mart\u00ednez N (2017) Splenic diffuse red pulp small B-cell lymphoma displays increased expression of cyclin D3 and recurrent CCND3 mutations. Blood 129(8):1042\u20131045. https:\/\/doi.org\/10.1182\/blood-2016-11-751024","journal-title":"Blood"},{"issue":"2","key":"4795_CR44","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1097\/pas.0000000000000523","volume":"40","author":"D Martinez","year":"2016","unstructured":"Martinez D, Navarro A, Martinez-Trillos A, Molina-Urra R, Gonzalez-Farre B, Salaverria I, Nadeu F, Enjuanes A, Clot G, Costa D, Carrio A, Villamor N, Colomer D, Martinez A, Bens S, Siebert R, Wotherspoon A, Be\u00e0 S, Matutes E, Campo E (2016) NOTCH1, TP53, and MAP2K1 Mutations in splenic diffuse red pulp small B-cell lymphoma are associated with progressive disease. Am J Surg Pathol 40(2):192\u2013201. https:\/\/doi.org\/10.1097\/pas.0000000000000523","journal-title":"Am J Surg Pathol"},{"issue":"10","key":"4795_CR45","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.3324\/haematol.2016.160192","volume":"102","author":"J Laurent","year":"2017","unstructured":"Laurent J, Lucile B, Pierre S, Sarah H, Kaddour C, Evelyne C-B, Aur\u00e9lie V, Sandrine H, Jean-Pierre D, David S, Nicolas L, Christophe B, Pascale F, Fran\u00e7oise B, Jean-Pierre M, Laurent G, Gilles S, Alexandra T-G (2017) Exome sequencing identifies recurrent BCOR alterations and the absence of KLF2, TNFAIP3 and MYD88 mutations in splenic diffuse red pulp small B-cell lymphoma. Haematologica 102(10):1758\u20131766. https:\/\/doi.org\/10.3324\/haematol.2016.160192","journal-title":"Haematologica"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-04795-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-022-04795-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-04795-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T10:09:56Z","timestamp":1651745396000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-022-04795-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,18]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["4795"],"URL":"https:\/\/doi.org\/10.1007\/s00277-022-04795-x","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2022,4,18]]},"assertion":[{"value":"1 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study has been approved by the institutional ethics committees of Institute of Hematology and Blood Disease Hospital. The procedures used in this study adhere to the tenets of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}